Immunization, Hib3 in OECD members
OECD members: Immunization, Hib3 was 91.0% in 2024. ▲ Rising
Immunization, Hib3 in OECD members, 1990–2024
Source: WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/). Measured in % of children ages 12-23 months.
Analysis
In 2024, immunization, hib3 in OECD members stood at 91.0%.
Compared with earlier readings it is down 1.3% on the previous year and down 2.4% over ten years.
Over the whole period, immunization, hib3 in OECD members peaked at 94.3% in 2016 and was at its lowest, 0.0%, in 1990.
That places OECD members 11th out of 43 groups with data for 2024, putting it in the top quarter.
The long-run direction has been consistently rising across the 35 years of available data.
Immunization, Hib3 in OECD members, year by year
| Year | % of children ages 12-23 months | Change |
|---|---|---|
| 1990 | 0.0% | — |
| 1991 | 3.7% | — |
| 1992 | 4.9% | +34.0% |
| 1993 | 9.7% | +95.1% |
| 1994 | 10.4% | +8.0% |
| 1995 | 31.9% | +205.7% |
| 1996 | 35.9% | +12.7% |
| 1997 | 39.5% | +10.0% |
| 1998 | 49.9% | +26.3% |
| 1999 | 52.6% | +5.5% |
| 2000 | 68.7% | +30.5% |
| 2001 | 69.4% | +1.0% |
| 2002 | 71.5% | +3.2% |
| 2003 | 73.9% | +3.3% |
| 2004 | 74.8% | +1.3% |
| 2005 | 75.9% | +1.4% |
| 2006 | 76.5% | +0.9% |
| 2007 | 84.0% | +9.8% |
| 2008 | 85.0% | +1.1% |
| 2009 | 83.1% | -2.1% |
| 2010 | 84.5% | +1.6% |
| 2011 | 92.3% | +9.2% |
| 2012 | 92.7% | +0.5% |
| 2013 | 90.0% | -3.0% |
| 2014 | 93.3% | +3.7% |
| 2015 | 93.4% | +0.1% |
| 2016 | 94.3% | +1.0% |
| 2017 | 92.8% | -1.6% |
| 2018 | 93.4% | +0.6% |
| 2019 | 92.4% | -1.1% |
| 2020 | 90.4% | -2.1% |
| 2021 | 91.4% | +1.1% |
| 2022 | 92.0% | +0.7% |
| 2023 | 92.3% | +0.3% |
| 2024 | 91.0% | -1.3% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 1990s | 23.8% | 0.0% | 52.6% | 10 |
| 2000s | 76.3% | 68.7% | 85.0% | 10 |
| 2010s | 91.9% | 84.5% | 94.3% | 10 |
| 2020s | 91.4% | 90.4% | 92.3% | 5 |
More health data for OECD members
- Population ages 40-44, male, annual growth rate -0.0796 % change on previous year (2025)
- Population ages 45-49, male, annual growth rate 0.5497 % change on previous year (2025)
- Population ages 45-49, female, per capita 0.0329 units per person (2025)
- Population ages 45-49, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 45-49, female, annual growth rate 0.5518 % change on previous year (2025)
- Population ages 40-44, male, per capita 0.0336 units per person (2025)
- Population ages 40-44, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, female, annual growth rate -0.2511 % change on previous year (2025)
- Population ages 35-39, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 35-39, male, per capita 0.0339 units per person (2025)
Frequently asked questions
- What is immunization, hib3 in OECD members?
- Immunization, hib3 in OECD members was 91.0% in 2024, according to WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).
- What is the highest immunization, hib3 recorded in OECD members?
- The highest recorded value was 94.3% in 2016.
- What is the lowest immunization, hib3 recorded in OECD members?
- The lowest recorded value was 0.0% in 1990.
- How does OECD members rank for immunization, hib3?
- OECD members ranks 11th out of 43 groups with data for 2024.
- Is immunization, hib3 rising or falling in OECD members?
- Over the last ten years it is down 2.4%. The long-run trend across the full record is rising.
- Where does this OECD members data come from?
- The figures come from WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as part of Immunization, Hib3 (% of children ages 12-23 months). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 35 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.